InvestorsHub Logo
Followers 87
Posts 6569
Boards Moderated 1
Alias Born 09/18/2009

Re: Corundum post# 25451

Friday, 02/26/2021 11:26:39 AM

Friday, February 26, 2021 11:26:39 AM

Post# of 42534
LOL, I might have to do something.

But, really, not only do I think I'm right, I think it makes sense that things are this way.

The market is finite. The worth of therapeutics, whether mAbs, molecules, etc., and regardless of the various methods of action, will all have value depending on how much market share they can obtain. I think the Covid stocks I have will all gain a piece of that action, if they are validated.
Assuming they all obtain about equal amounts of the market, share price will be justifiably established, and HGEN will show higher EPS due to having far fewer shareholders than these other companies. Of course, if lenz proves much more effective, that will be a big determinant of EPS, too. I still have 66% of my account in HGEN, and I am just riding it out until each of the companies I have complete their trials.